Chest
Original Research: CopdCOPD Prevalence in Salzburg, Austria: Results From the Burden of Obstructive Lung Disease (BOLD) Study
Section snippets
Materials and Methods
We followed the BOLD protocol as has been reported elsewhere.14All staff participated in training, supervised by the BOLD operations center.
Results
Table 1summarizes the main characteristics of the 1,258 individuals included in this analysis. Former smoking was more prevalent in men (p < 0.001), while current smoking was slightly higher in women (p < 0.067). Not surprisingly, workplace dust exposure was reported by 35.3% of men, but by only 18.2% of women (p < 0.001).
Compared with these participants, the 824 eligible individuals who were excluded from the analysis (nonrespondents and those with poor quality spirometry results) were more
Discussion
The key findings of this population-based prevalence survey are that one quarter of residents of Salzburg County, Austria, ≥ 40 years of age had at least mild airflow obstruction, and that this was as common in women as in men. This finding illustrates the magnitude of the burden that COPD will pose in the near future, as the proportion of the population living into the chronic disease age range continues to increase.1
To set this study in perspective, the sparse literature on COPD prevalence
Acknowledgments
We thank Terry Kimes for her assistance with analyzing the data. We also thank the whole Austrian BOLD team involved with the study.
References (30)
- et al.
Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study
Lancet
(1997) - et al.
Interpreting COPD prevalence estimates: what is the true burden of disease?
Chest
(2003) - et al.
Chronic obstructive pulmonary disease in five Latin American cities (the Platino study): a prevalence study
Lancet
(2005) - et al.
Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study
Respir Med
(2006) - et al.
Trends in the leading causes of death in the United States, 1970–2002
JAMA
(2005) - et al.
Population impact of different definitions of airway obstruction
Eur Respir J
(2003) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at
- et al.
ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
Eur Respir J
(2004) - et al.
Obstructive lung disease and low lung function in adults in the United States
Arch Intern Med
(2000) - et al.
COPD in Japan: the Nippon COPD Epidemiology study
Respirology
(2004)
Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey
Am J Respir Crit Care Med
Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC Multicentre Epidemiological Study
Chest
Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease: the Lung Health Study Research Group
Am J Respir Crit Care Med
The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design
COPD
Standardization of spirometry, 1994 update
Am J Respir Crit Care Med
Cited by (128)
COPD exacerbations are related to poor air quality in Innsbruck: A retrospective pilot study
2021, Heart and LungCitation Excerpt :In 2016, nearly 6% of all-cause mortality in Austria was related to respiratory diseases, leading to a severe economic burden.2,3 According to the World Health Organization (WHO), COPD is now the third leading cause of death worldwide, and approximately one-quarter of the Austrian population aged over 40 is expected to suffer from COPD.4–6 Even though its main driver is cigarette smoking, around 25% of people affected by COPD have never smoked.7
Perception of Quality of Life in Patients With Chronic Obstructive Pulmonary Disease in Spain
2019, Open Respiratory ArchivesThe prevalence of chronic airflow obstruction in three cities in the Nordic-Baltic region
2018, Respiratory Medicine
The BOLD project in Salzburg, Austria, was funded by unrestricted grants from Altana; Astra-Zeneca; Boehringer-Ingelheim; GlaxoSmithKline; Merck, Sharpe & Dohme; Pfizer; and Novartis. GlaxoSmithKline also provided in-kind contributions. The study was supported by the “Salzburger Gebietskrankenkasse” (local public health insurance) and the local government of Salzburg. The BOLD Initiative is funded by unrestricted educational grants from ALTANA, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, and Pfizer to the Operations Center located at the Center for Health Research in Portland, OR (www.boldcopd.org).
The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestjournal.org/misc/reprints.shtml).